{"id":"NCT05529992","sponsor":"Takeda","briefTitle":"A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease","officialTitle":"A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-03","primaryCompletion":"2024-08-05","completion":"2024-08-05","firstPosted":"2022-09-07","resultsPosted":"2025-02-26","lastUpdate":"2025-06-26"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease"],"interventions":[{"type":"DRUG","name":"Velaglucerase Alfa","otherNames":["VPRIV"]}],"arms":[{"label":"Velaglucerase Alfa (VPRIV)","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to observe the side effects of VPRIV in participants with type 1 Gaucher disease who are either treatment-na√Øve (newly diagnosed) or who are currently being treated with enzyme replacement therapy (ERT).\n\nParticipants will receive VPRIV intravenously during the treatment period (up to 51 weeks), followed by the end-of-treatment (EOT) visit after 2 weeks.","primaryOutcome":{"measure":"Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE)","timeFrame":"Up to 56.2 weeks","effectByArm":[{"arm":"VPRIV","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/fba4cdf09dab492e?idFilter=%5B%22TAK-669-3001%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":20},"commonTop":["Upper respiratory tract infection","Cough","Pyrexia","Conjunctivitis","Fall"]}}